Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 45 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/14/2008 First Published: 2/21/2003


1.		Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40- Ligand and Denileukin Diftitox in Patients With HLA-A1- and/or HLA-A2.1-Positive Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				over 18				Other				ERLANGEN-ONTAK EU-20246, NCT00056134

Last Modified: 11/14/2008 First Published: 11/20/2003


2.		Phase I/II Study of Vaccination With Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding For Melan-A, MAGE-3, and Survivin Antigens in Patients With Stage IV Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				ERLANGEN-DERMA-ER-DC-06 EU-20317, NCT00074230


3.		The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 65				Other				pepDCIL2- HMO-CTIL NCT00279058


4.		Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				Other				immatureDC- HMO-CTIL NCT00278018


5.		Combined Modality Treatment for Patients With Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				21 to 75				Other				Baylor IRB #006-025-01 0000, NCT00313235


6.		Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				RDA-0537 NCT00345293


7.		Dendritic Cell Based Therapy of Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				UR0414 NCT00197860


8.		Dendritic Cell Based Therapy of Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				MM0413 NCT00197912


9.		Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic CA

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				Other				PANC0003 95935, e1454, NCT00547144

Last Modified: 1/7/2009 First Published: 2/27/2008


10.		Phase I/II Randomized Study of Cytomegalovirus-Specific T-Cell Adoptive Transfer in Patients With Newly Diagnosed Glioblastoma Multiforme Who Are Recovering From Therapeutic Temozolomide-Induced Lymphopenia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Diagnostic, Treatment				Active				18 and over				NCI				DUMC-PRO00000580 PRO00000580, DUMC-SPORE Project 3, NCT00627224

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute